Ameriprise
ODT

Ameriprise’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Ameriprise’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8,125
Closed -$345K – 3816
2020
Q2 		$345K Sell
8,125
-16,252
-67% -$526K ﹤0.01% 3316
2020
Q1 		$672K Sell
24,377
-3,010
-11% -$87.8K ﹤0.01% 2995
2019
Q4 		$890K Sell
27,387
-1,050
-4% -$32.5K ﹤0.01% 3106
2019
Q3 		$738K Sell
28,437
-50,490
-64% -$1.69M ﹤0.01% 3137
2019
Q2 		$2.9M Buy
78,927
+1,637
+2% +$39.2K ﹤0.01% 2547
2019
Q1 		$1.71M Sell
77,290
-995
-1% -$17.4K ﹤0.01% 2809
2018
Q4 		$1.1M Sell
78,285
-61,164
-44% -$952K ﹤0.01% 2903
2018
Q3 		$2.71M Sell
139,449
-1,995
-1% -$40.7K ﹤0.01% 2689
2018
Q2 		$3.12M Buy
141,444
+5,212
+4% +$121K ﹤0.01% 2529
2018
Q1 		$2.89M Sell
136,232
-3,524
-3% -$83.1K ﹤0.01% 2529
2017
Q4 		$3.5M Buy
+139,756
New +$3.3M ﹤0.01% 2357

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ameriprise's ODT Position: Q3 2020 in Review

Ameriprise sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2020, closing a stake of 8,125 shares — an estimated $345K sold.

Ameriprise first reported a position in ODT in Q4 2017 and held it in 11 quarters. The position peaked at $3.5M in Q4 2017. 89 funds tracked by Wall St. Rank hold ODT as of Q3 2020.

  • Ameriprise reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Ameriprise sold 8,125 Odonate Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $345K.
  • Ameriprise first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 11 quarters.
  • Ameriprise's Odonate Therapeutics, Inc. Common Stock position peaked at $3.5M in Q4 2017.
  • 89 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Ameriprise's 13F filing for Q3 2020, filed 16 Nov 2020.